Drugs / Diclofenac diethylamine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03497039 | Jul 2018 → Mar 2019 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT04052620 | Oct 2019 → Nov 2020 | — | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00955513 | Jul → Dec 2009 | — | Novartis | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00573768 Comparator | Nov → Dec 2007 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT03434197 Comparator | Feb 2018 → Jan 2021 | osteoarthritis, knee | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diclofenac Diethylamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03497039 ↗ |
| Known as | DDEA | “Diclofenac diethylamine (DDEA) gel has demonstrated efficacy for treatment of ankle sprains in both the 1.16% four-times-daily (QID) and 2.32% twice-daily (BID) formulations.” PMID 36566202 ↗ Dec 20221“Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA.” NCT03497039 ↗ |
| Route | Topical | “Diclofenac Diethylamine 2.32% Gel Applied Once or Twice Daily” NCT00573768 ↗ |